15 results
6-K
EX-99.1
GLPG
Galapagos NV
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
endpoints the study will also evaluate the effects on Health-Related Quality of Life (HRQoL) scores and Health Care Resource Utilization (HCRU) at Week
6-K
EX-99.1
GLPG
Galapagos NV
13 Aug 20
Current report (foreign)
9:42am
and pharma along the health care value chain to bring precision medicine to autoimmune diseases.
Scipher Medicine is backed by Khosla Ventures
6-K
EX-99.3
uzachje iuk4rqqv5qn
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.2
ub00nt14 rav
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
20-F
0xyfwg p40xu
25 Mar 16
Annual report (foreign)
12:00am
DRS/A
EX-10
6d3khy
4 Mar 15
Draft registration statement (amended)
12:00am
DRS/A
EX-10
0rt6r5ybndktk
4 Mar 15
Draft registration statement (amended)
12:00am
DRS
q4xfsw7x
6 Feb 15
Draft registration statement
12:00am
- Prev
- 1
- Next